Request Demo
Last update 08 May 2025
ZG-005
Last update 08 May 2025
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
19
Clinical Trials associated with ZG-005NCT06938880
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors, Including Cervical Cancer, Hepatocellular Carcinoma, Neuroendocrine Tumors, and Lung Cancer
NCT06883526
A Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
NCT06927687
A Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of ZG005 in Patients With Advanced Solid Tumors
100 Clinical Results associated with ZG-005
Login to view more data
100 Translational Medicine associated with ZG-005
Login to view more data
100 Patents (Medical) associated with ZG-005
Login to view more data
100 Deals associated with ZG-005
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 26 Mar 2025 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 25 Mar 2025 | |
| Recurrent Lymphoma | Phase 2 | China | 13 Mar 2025 | |
| Refractory Lymphoma | Phase 2 | China | 13 Mar 2025 | |
| Advanced biliary tract cancer | Phase 2 | China | 04 Mar 2025 | |
| Advanced Hepatocellular Carcinoma | Phase 2 | China | 22 Oct 2024 | |
| Advanced Neuroendocrine Carcinoma | Phase 2 | China | 24 May 2024 | |
| Advanced Cervical Carcinoma | Phase 2 | China | 18 Mar 2024 | |
| Solid tumor | Phase 2 | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | Advanced Hepatocellular Carcinoma First line | 10 | (kabidfxcua) = cjgmaaekut tfxvnxjjao (gaxqsrzxgg ) View more | Positive | 25 Sep 2024 | ||
CTR20220021 (NEWS) Manual  | Phase 1/2 | 46 | (rezanxwnqn) = pgwhzsiepj ulinnvtnwk (zkbfbjrgua ) View more | Positive | 25 Sep 2024 | ||
(20 mg/kg) | (rezanxwnqn) = cnkddwgtsg ulinnvtnwk (zkbfbjrgua ) View more | ||||||
CTR20220021 (ASCO2024) Manual | Phase 1 | 57 | (tcwhvogeoy) = zmsmvexenc wycwzqqdhb (hdsyhyqdeg ) View more | Positive | 24 May 2024 | ||
(cervical cancer) | (tcwhvogeoy) = njywnxejgc wycwzqqdhb (hdsyhyqdeg ) View more | ||||||
Phase 1 | 16 | (dfxhganomh) = uvkptnlsii uomardsenh (hgrxkworcv ) View more | Positive | 26 May 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free